Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: Effects of enalapril

Atherosclerosis

Volumn 130, Issue 1-2, 1997, Pages 53-59

  Hoshida, Shiro ^a   Nishida, Masashi ^a   Yamashita, Nobushige ^a   Igarashi, Junsuke ^a   Aoki, Kazuhiro ^a   Hori, Masatsugu ^a   Kuzuya, Tsunehiko ^a   Tada, Michihiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

ACE activity; angiotensin II; atherosclerosis; enalapril

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; ARTERIOSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL, DIETARY; ENALAPRIL; MALE; PEPTIDYL-DIPEPTIDASE A; RABBITS;

EID: 0030991378     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06045-5     Document Type: Article

References (46)

1. Okamura T, Miyazaki M, Inagami T, Toda N. Vascular reninangiotensin system in two-kidney, one clip hypertensive rats. Hypertension 1986;8:560.
2. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18(Suppl II):II-100.
3. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects of coronary resistance, contractility and relaxation. J Clin Invest 1990;86:1913.
4. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95.
5. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749.
6. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456.
7. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by antiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419.
8. + + mobilization and protein kinase C activation. J Biol Chem 1989;264:526.
9. Carretero OA, Miyazaki S, Scicli AG. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981;3:18.
10. Becker RHA, Weimer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18(Suppl 2):S110.
11. Ross R. The pathogenesis of atherosclerosis; a perspective for the 1990s. Nature 1993;362:801.
12. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in Cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15(Suppl 5):S65.
13. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327.
14. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993;91:1453.
15. Jacobson LS, Persson K, Aberg G, Andersson RGG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994;24:670.
16. Allain CA, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Chin Chem 1974;20:470.
17. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1970;20:1637.
18. Hoshida S, Nishida M, Yamashita N, Igarashi J, Hori M, Kamada T, Kuzuya T, Tada M. Amelioration of the severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet. J Am Coll Cardiol 1996;27:902.
19. 1-Adrenergic receptor blockage reduces the AII-induced vascular SMC DNA synthesis in the rat thoracic aorta and carotid artery. Circ Res 1992;70:1122.
20. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest 1995;96:141.
21. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626.
22. Herrmann HC, Dzau VJ. The feedback regulation of angiotensinogen production by components of the renin-angiotensin system. Circ Res 1983;52:328.
23. Fishel RS, Thourani V, Eisenberg SJ, Shai SY, Corson MA, Nabel EG, Bernstein KE, Berk BC. Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. J Clin Invest 1995;95:377.
24. Krulewitz AH, Fanburg BL. The effect of oxygen tension on the in vitro production and release of angiotensin-converting enzyme by bovine pulmonary artery endothelial cells. Am Rev Respir Dis 1984;130:866.
25. King SJ, Booyse FM, Lin P-H, Traylor M, Narkates AJ, Oparil S. Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis. Am J Physiol 1989;256:C1231.
26. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987;79:170.
27. Jayakody L, Senaratne M, Thomson A, Kappagoda T. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 1987;60:251.
28. Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524.
29. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866.
30. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(Suppl I):I-4.
31. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982;220:63.
32. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992;86:1566.
33. Negoro N, Kanayama Y, Iwai J, Umetani N, Nishimura M, Konishi Y, Okamura M, Inoue T, Takeda T. Angiotensin-converting enzyme inhibitor increases angiotensin type 1A receptor gene expression in aortic smooth muscle cells of spontaneously hypertensive rats. Biochim Biophys Acta 1994;1226:19.
34. Rolland P-H, Charpiot P, Friggi A, Piquet P, Barlatier A, Scalbert E, Bodard H, Tranier P, Mercier C, Luccioni R, Garcon D. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am J Cardiol 1993;71:22E.
35. Riezebos J, Vleeming W, Beems RB, van Amsterdam JGC, Meijer GW, de Wildt DJ, Porsius AJ, Wemer J. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits. I. Effect on progression of atherosclerosis and endothelial dysfunction. J Cardiovasc Pharmacol 1994;23:415.
36. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
37. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1992;20:473.
38. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 1993;88(Suppl 1):1.
39. Sharpe N. The effects of ACE inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol 1993;22(Suppl 9):S9.
40. Lopez JAG, Armstrong ML, Harrison DG, Piegors DJ, Heistad DD. Responsiveness of iliac collateral vessels to constrictor stimuli in atherosclerotic primates. Circ Res 1988;63:1020.
41. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2:277.
42. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883.
43. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348.
44. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669.
45. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E, on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of Survival and Ventricular Enlargement Trial. Circulation 1994;90:1731.
46. Gruppo Italiano per lo Studio della Sopravvivenza nell 'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115.